Q-omics provides the consensus-scored UROD profile across patient tissues and cancer cell-line models. UROD expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in LIHC. Among the 18 cancer types available for tumor–normal comparison, UROD is differentially expressed in 14, with the highest sampling consensus in KIRC. Additionally, UROD protein abundance shows 23,229 significant protein co-abundance associations, with the highest sampling consensus in PDAC. Together, these results highlight LIHC, KIRC, and PDAC as cancer lineages where UROD shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for UROD — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes UROD survival associations across molecular data types. UROD RNA expression shows survival associations in the most cancer types (22), followed by mutation status (5) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible UROD RNA expression–survival associations across cancer types. High UROD expression shows unfavorable associations in LIHC, KICH, LGG and BLCA, but favorable associations in LUAD and SCLC. The LIHC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify LIHC as the clearest survival context for UROD RNA expression.
This table summarizes UROD tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14, while mass-spec protein shows differences in 9. The strongest signals are observed in KIRC for RNA and COAD for protein.
This table ranks reproducible tumor–normal expression differences for UROD. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. UROD shows lower tumor expression in KICH, BRCA and THCA and higher tumor expression in KIRC, LIHC and HNSC. The KIRC box plot shows higher UROD RNA expression in tumor versus normal tissue (log2 FC = +0.728, t-test p < 0.001).
This table shows molecular features associated with UROD in patient tissues and cancer cell lines. In patient samples, UROD shows the broadest associations at the RNA and protein expression levels, with PDAC recurring as the lineage with the largest associated feature set. In cancer cell lines, UROD RNA and mutation anchors are most strongly linked to RNA-expression features, especially in CNS, while CRISPR and shRNA rows add functional-dependency signals in LUNG_NSCLC_LUSC and BLOOD_Leukemia.
